Evidence Hub

The Effect of Valproic Acid and Furosemide on the Regulation of the Inflammasome Complex (NLRP1 and NLRP3 mRNA) in the Brain of Epileptic Animal Model

Aref Samadianzakaria, Z. Abdolmaleki, F. Faedmaleki

Brain Research Bulletin, 2022

15 citations

Abstract

OBJECTIVES

This study aimed to explore the effect of concomitant use of Furosemide (FRS) and Valproic acid (VPA), demonstrating anti-inflammation efficacy, on epilepsy, and its underlying mechanism.

METHODS

Twenty-five adult male Wistar rats were divided into five groups including, Group 1: (Normal) rats received no drugs, Group 2: (E): rats were administered with a single dose of kainic acid (stereotaxic surgery), Group 3: (E+VPA): rats received Valproic acid (200mg/kg/day/orally), Group 4: (E+FRS): rats received a single dose of Furosemide (100mg/kg/I.P.) 30min before epilepsy induction, Group 5: (E+VPA (200mg/Kg)+FRS (100mg/Kg, combination treatment). The treatment group received VPA for 14 days. We assessed seizures based on modified Racine΄s scores and conducted the electroencephalographic (EEG) recording. NLRP1 and NLRP3 mRNA levels, Apoptosis-associated Speck-like protein containing a caspase recruitment domain (ASC), absence in melanoma2 (AIM2) protein expression levels, and apoptosis rate of the brain cells were analyzed utilizing real-time PCR, immunohistochemistry, and tunnel assay, respectively.

RESULTS

The results revealed that FRS and VPA treatment, alone or in combination, improved behavioral outcome and reduced seizure intensity in epileptic rats. The combination therapy significantly decreased the apoptosis rate NLRP1 and NLRP3 gene as well as ASC and AIM2 protein expression levels.

CONCLUSION

Combination therapy protected the brain against neuronal damages…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free